Radiofrequency Ablation in Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02281812|
Recruitment Status : Terminated (Increased infection rate in study group)
First Posted : November 4, 2014
Last Update Posted : August 10, 2017
Background/Main objective: Radiofrequency ablation (RFA) is a minimally invasive procedure widespread accepted in the treatment of different tumors, especially in the liver but its benefit is not yet well-known in breast cancer.
Our main objective is to evaluate the usefulness of RFA in < 2cm malignant breast tumors to reduce the proportion of positive margins.
Methodology: The investigator propose a single-center, single-blind, phase I and II randomized controlled trial. Phase I:Security of the cool-tip cluster electrode assessing the potential adverse effects in three stages: initial,intermediate and final. Phase II: Randomized clinical trial, 2 parallel groups with 37 patients in each one.
Experimental group: percutaneous RFA previous to conventional lumpectomy. Control group: conventional surgery with lumpectomy. The number of positive margins in both groups, and the need of extending margin resection will be assessed intraoperatively. Inclusion criteria: women >40 years, infiltrating ductal breast carcinoma by biopsy. The tumor must be unique, visible by ultrasound, smaller than 2cm and located > 1 cm from the chest wall and the skin. Patients will be followed up for a period of two years to assess cosmetic result, short -term and long -term complications and recurrences.
Expected results: The "cool-tip" (cluster) ablation method reduces by at least 30% the risk of intraoperative extensions for positive margins during lumpectomy compared to conventional surgery in breast tumors with a diameter < 2 cm.
Therefore this procedure may reduce the risk of second surgeries and the removed volume of tissue.Consequently the final cosmetic result should be improved.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Procedure: Radiofrequency ablation|
Main objectives of the project:
- To evaluate the usefulness of radiofrequency ablation (RFA) to achieve a lower percentage of positive margins.
- To validate clinically the efficacy and safety of the method in breast tumors smaller than < 2 cm.
Specific objectives of the project:
To demonstrate that , after RFA, clear margins are increased in the intraoperative pathological analysis compared to conventional surgery.
- To quantify the number of positive margins requiring intraoperative extension in each patient, comparing the ratio in both groups.
- To quantify the percentage of patients requiring intraoperative extension compared in both groups.
To demonstrate a reduction in the volume of breast tissue removed after RFA compared to conventional surgery.
- Comparing in both groups the anteroposterior, transverse and craniocaudal diameters of the excised specimen, measured in cm, and to calculate the volume.
- Tumor weight in grams (including extensions) will be measured to compare the weights in both groups.
To evaluate the differences in cosmetic outcome after RFA versus conventional surgery.
a. An international scale will be used and the scores will be compared. There will be two independent assessments, one for the physician and another for the patient.
To demonstrate the effectiveness of the RFA by cluster "cool-tip" electrode in the experimental group.
- RFA is considered as complete when no viable tumor tissue is evidenced by oxidation-reduction reaction mediated by NADH-diaphorase after surgical resection. Mitochondrial dysfunction will be also evaluated by semiquantitative and quantitative method using the enzyme cytochrome c oxidase or Complex IV (COX) and tunel. Any residual viable tumor tissue will be considered as incomplete RFA.
- Risk factors for incomplete ablations will be analyzed, especially tumor vascularization.
- To demonstrate the safety of RFA by cluster "cool-tip" electrode in breast cancer tumors a. To quantify all side effects that may occur after the RFA and / or surgery and to correlate the complication rate in each group with severity.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Impact of Radiofrequency Ablation on Surgical Margins in Early Stage of Malignant Breast Tumors|
|Study Start Date :||September 2013|
|Primary Completion Date :||July 2017|
|Study Completion Date :||July 2017|
Experimental: RFA group
A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
Procedure: Radiofrequency ablation
After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
No Intervention: Control group
Normal excision of the tumor according to the protocol
- Intraoperative free margins (distance between the tumor and the margin in order to indicate if extensions are mandatory.) [ Time Frame: 1 hour ]The pathologist performed a macroscopic study of the specimen, measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory.
- Security of RFA (Adverse effects and cosmetic result) [ Time Frame: 15 days ]Adverse effects and cosmetic result will be evaluated 15 days after the procedure
- Efficacy of RFA (Tumoral viability in the ablation zone) [ Time Frame: 7 days ]Tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunel
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02281812
|Hospital Universitario Bellvitge|
|Hospitalet de Llobregat, Barcelona, Spain, 08908|
|Principal Investigator:||Amparo Garcia-Tejedor, MDPhD||Hospital Universitario Bellvitge-Idibell_Universidad de Barcelona|